Novartis AG (SWX:NOVN)
99.21
+1.66 (1.70%)
Jul 10, 2025, 5:39 PM CET
Novartis AG Revenue
Novartis AG had revenue of $13.62B USD in the quarter ending March 31, 2025, with 12.38% growth. This brings the company's revenue in the last twelve months to $53.22B, up 11.50% year-over-year. In the year 2024, Novartis AG had annual revenue of $51.72B with 10.85% growth.
Revenue (ttm)
$53.22B
Revenue Growth
+11.50%
P/S Ratio
4.13
Revenue / Employee
$701.37K
Employees
75,883
Market Cap
194.38B CHF
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 62.40B |
Lonza Group AG | 6.57B |
Alcon | 8.77B |
Galderma Group AG | 4.02B |
Sandoz Group AG | 9.41B |
Straumann Holding AG | 2.50B |
Sonova Holding AG | 3.87B |
Ypsomed Holding AG | 748.87M |
Novartis AG News
- 9 hours ago - Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement on Cosentyx® for hidradenitis suppurativa (HS) - Benzinga
- 2 days ago - Novartis (NVS) Gains Approval for Infant Malaria Treatment - GuruFocus
- 2 days ago - Novartis wins approval for first malaria drug for newborns - Financial Times
- 2 days ago - Novartis wins Swiss approval for Coartem Baby, first malaria drug for infants and young children - Seeking Alpha
- 2 days ago - Novartis gets approval for first malaria drug for babies and children - Reuters
- 2 days ago - Novartis receives approval for first malaria medicine for newborn babies and young infants - GlobeNewsWire
- 7 days ago - Novartis' Cosentyx Fails Late-Stage Giant Cell Arteritis Trial - Benzinga
- 7 days ago - Novartis fails in late-stage trial for Cosentyx in giant cell arteritis - Seeking Alpha